Product image of Linagliptin Viatris (Linagliptin) supplied by GNH India

Linagliptin Viatris

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptin Viatris (Linagliptin)

Linagliptin, the active ingredient in Linagliptin Viatris, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise.

GNH India supplies Linagliptin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.
  • Type 2 diabetes mellitus (monotherapy): improves blood glucose control as a single oral agent.
  • Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to metformin, sulfonylureas or insulin.
  • Type 2 diabetes mellitus (renal impairment): can be used without dose adjustment, providing an option for patients with reduced kidney function.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of endogenous incretin hormones such as GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion and suppress glucagon release, resulting in lower post‑prandial and fasting plasma glucose concentrations.

Side Effects

Common Side Effects

  • Upper respiratory tract infection: mild symptoms such as sore throat or nasal congestion.
  • Nasopharyngitis: inflammation of the nasal passages and throat.
  • Headache: transient mild to moderate headache.
  • Gastrointestinal discomfort: occasional nausea or abdominal pain.
  • Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe hypersensitivity reactions: rash, angioedema or anaphylaxis.
  • Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Acute kidney injury: rare but possible decline in renal function.
  • Bullous skin eruptions: blistering skin reactions.

Precautions & Warnings

  • Before prescribing Linagliptin, clinicians should consider the following precautions.
  • Renal impairment: no dose adjustment needed, but monitor renal function regularly.
  • Hepatic impairment: use with caution in patients with moderate to severe liver disease.
  • Pregnancy: Category B; prescribe only if the potential benefit justifies the potential risk to the fetus.
  • Elderly patients: monitor for hypoglycaemia, especially when used with insulin or sulfonylureas.
  • Drug interactions: review concomitant medications for agents that may affect glucose levels.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Linagliptin may interact with several co‑administered medicines.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of hypoglycaemia.
  • Strong P‑glycoprotein inhibitors (e.g., itraconazole): may raise linagliptin exposure.

Moderate Interactions (Monitor Closely)

  • Rifampin: may reduce linagliptin plasma concentrations.
  • Diuretics: may affect glucose homeostasis, requiring closer monitoring.
  • ACE inhibitors: watch for additive blood pressure effects.

Frequently Asked Questions

Linagliptin Viatris is used to improve glycaemic control in adults with type 2 diabetes mellitus. It can be prescribed as monotherapy or in combination with other oral antidiabetic agents, insulin, or lifestyle interventions to help lower blood glucose levels.

Linagliptin works by selectively inhibiting the DPP‑4 enzyme, which prolongs the activity of incretin hormones such as GLP‑1 and GIP. These hormones increase insulin secretion and reduce glucagon release in a glucose‑dependent manner, thereby lowering blood glucose concentrations.

The specific dose of Linagliptin Viatris is determined by the prescribing healthcare professional based on the individual patient's clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Linagliptin is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used during pregnancy only if the potential benefit justifies the potential risk. Breastfeeding is not recommended unless the benefit outweighs the risk.

To order Linagliptin Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Linagliptin shares the same mechanism of action as other DPP‑4 inhibitors but differs in its pharmacokinetic profile; it is primarily excreted unchanged via the bile, allowing use without dose adjustment in renal impairment, unlike some alternatives that require renal dosing modifications.

Linagliptin tablets should be stored at ambient temperature, below 25 °C, in their original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Linagliptin Viatris is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and hypoglycaemia when used together with insulin or sulfonylureas. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of low blood sugar.

Linagliptin is contraindicated in patients with a known hypersensitivity to linagliptin or any of its excipients. It should also be avoided in individuals with a history of severe pancreatitis until the cause is identified and resolved.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT